{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:32:26Z","timestamp":1775208746353,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jss.2020.06.016","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:18:56Z","timestamp":1594901936000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma"],"prefix":"10.1016","volume":"256","author":[{"given":"John F.","family":"Tierney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyx","family":"Vogle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Finnerty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasa","family":"Zarnegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Ghai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas J.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier M.","family":"Keutgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2020.06.016_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.jss.2020.06.016_bib2","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2020.06.016_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jss.2020.06.016_bib4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2020.06.016_bib5","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1007\/s13277-014-1859-3","article-title":"Ido is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis","volume":"35","author":"Isla Larrain","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jss.2020.06.016_bib6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6603477","article-title":"Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer","volume":"95","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2020.06.016_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-017-0285-7","article-title":"Objective measurement and clinical significance of Ido1 protein in hormone receptor-positive breast cancer","volume":"5","author":"Carvajal-Hausdorf","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jss.2020.06.016_bib8","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of Ido1 inhibitors: from Bench to Bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2020.06.016_bib9","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","article-title":"Discovery of a novel and selective indoleamine 2,3-dioxygenase (Ido-1) inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate","volume":"60","author":"Crosignani","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.jss.2020.06.016_bib10","doi-asserted-by":"crossref","first-page":"91914","DOI":"10.18632\/oncotarget.20166","article-title":"The Ido inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells","volume":"8","author":"Lewis","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jss.2020.06.016_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/2326-6066.CIR-17-0223","article-title":"Antigen-specific antitumor responses induced by OX40 agonist are enhanced by the IDO inhibitor indoximod","volume":"6","author":"Berrong","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jss.2020.06.016_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.surg.2018.04.086","article-title":"Expression of programmed death ligand-1 and 2 in adrenocortical cancer tissues: an exploratory study","volume":"165","author":"Tierney","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.jss.2020.06.016_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00000658-199307000-00004","article-title":"Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors","volume":"218","author":"Stierer","year":"1993","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2020.06.016_bib14","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2020.06.016_bib15","series-title":"IBM SPSS statistics for Windows","year":"2013"},{"key":"10.1016\/j.jss.2020.06.016_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.10645","article-title":"Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection","volume":"101","author":"Friberg","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2020.06.016_bib17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/cas.13560","article-title":"High Ido-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma","volume":"109","author":"Seeber","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jss.2020.06.016_bib18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-16-0150","article-title":"Differential expression and significance of PD-L1, Ido-1, and B7-H4 in human lung cancer","volume":"23","author":"Schalper","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2020.06.016_bib19","first-page":"82","article-title":"Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells","volume":"30","author":"Sun","year":"2011","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.jss.2020.06.016_bib20","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2020.06.016_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12032-015-0694-8","article-title":"Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer","volume":"32","author":"Salvadori","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.jss.2020.06.016_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12185-015-1835-8","article-title":"Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice","volume":"102","author":"Nakamura","year":"2015","journal-title":"Int J Hematol"},{"issue":"Suppl l","key":"10.1016\/j.jss.2020.06.016_bib23","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/JCO.2017.35.15_suppl.3066","article-title":"A phase II randomized, double-blind study of sipuleucel-T followed by Ido pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"35","author":"Jha","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2020.06.016_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jss.2020.06.016_bib26","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1530\/EC-18-0398","article-title":"Immunotherapy failure in adrenocortical cancer: where next?","volume":"7","author":"Cosentini","year":"2018","journal-title":"Endocr Connect"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480420303991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480420303991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:49:33Z","timestamp":1758379773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480420303991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"alternative-id":["S0022480420303991"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2020.06.016","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}